Cipla eyes China presence through Meditab buy
This article was originally published in Scrip
Executive Summary
Cipla expects its recent acquisition of the domestic firm, Meditab Specialities, to facilitate an entry into the Chinese formulations market, as well as opening up opportunities for the company in Africa.